NDC 71205-411

Oxcarbazepine

Oxcarbazepine

Oxcarbazepine is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Proficient Rx Lp. The primary component is Oxcarbazepine.

Product ID71205-411_0f92415d-6d81-4cc1-9a3b-028430951eb8
NDC71205-411
Product TypeHuman Prescription Drug
Proprietary NameOxcarbazepine
Generic NameOxcarbazepine
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2007-10-09
Marketing CategoryANDA / ANDA
Application NumberANDA077802
Labeler NameProficient Rx LP
Substance NameOXCARBAZEPINE
Active Ingredient Strength150 mg/1
Pharm ClassesAnti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 71205-411-30

30 TABLET, FILM COATED in 1 BOTTLE (71205-411-30)
Marketing Start Date2020-02-26
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 71205-411-90 [71205041190]

Oxcarbazepine TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA077802
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2020-02-26

NDC 71205-411-60 [71205041160]

Oxcarbazepine TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA077802
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2020-02-26

NDC 71205-411-30 [71205041130]

Oxcarbazepine TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA077802
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2020-02-26

Drug Details

Active Ingredients

IngredientStrength
OXCARBAZEPINE150 mg/1

OpenFDA Data

SPL SET ID:95867dcd-fd0e-4570-987b-d35939f7d7d1
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 312136

    • Pharmacological Class

    • Anti-epileptic Agent [EPC]
    • Decreased Central Nervous System Disorganized Electrical Activity [PE]

    NDC Crossover Matching brand name "Oxcarbazepine" or generic name "Oxcarbazepine"

    NDCBrand NameGeneric Name
    0054-0097OxcarbazepineOxcarbazepine
    0054-0098OxcarbazepineOxcarbazepine
    0054-0099OxcarbazepineOxcarbazepine
    0054-0199OxcarbazepineOxcarbazepine
    0615-6593OxcarbazepineOxcarbazepine
    0615-6594OxcarbazepineOxcarbazepine
    0615-6595OxcarbazepineOxcarbazepine
    0615-8153OxcarbazepineOxcarbazepine
    68084-853OxcarbazepineOxcarbazepine
    68094-123OxcarbazepineOxcarbazepine
    68084-867OxcarbazepineOxcarbazepine
    68084-845OxcarbazepineOxcarbazepine
    68462-138OxcarbazepineOxcarbazepine
    68462-139OxcarbazepineOxcarbazepine
    68462-137OxcarbazepineOxcarbazepine
    68788-7306OxcarbazepineOxcarbazepine
    70518-0111OxcarbazepineOxcarbazepine
    70518-1073OxcarbazepineOxcarbazepine
    70518-1027OxcarbazepineOxcarbazepine
    70518-0894OXCARBAZEPINEOXCARBAZEPINE
    70518-1055OxcarbazepineOxcarbazepine
    70518-1980OxcarbazepineOxcarbazepine
    70518-1842OxcarbazepineOxcarbazepine
    71335-0090OXCARBAZEPINEOXCARBAZEPINE
    71335-0410OxcarbazepineOxcarbazepine
    71335-0505OxcarbazepineOxcarbazepine
    71335-0978OxcarbazepineOxcarbazepine
    0781-6270OxcarbazepineOxcarbazepine
    21695-863OxcarbazepineOxcarbazepine
    21695-862OxcarbazepineOxcarbazepine
    21695-864OxcarbazepineOxcarbazepine
    33261-842OxcarbazepineOxcarbazepine
    33261-841OxcarbazepineOxcarbazepine
    33261-684OxcarbazepineOxcarbazepine
    50090-2573OxcarbazepineOxcarbazepine
    50090-3961OxcarbazepineOxcarbazepine
    51672-4105OxcarbazepineOxcarbazepine
    51672-4107OxcarbazepineOxcarbazepine
    51672-4106OxcarbazepineOxcarbazepine
    51991-294OXCARBAZEPINEOXCARBAZEPINE
    51991-293OXCARBAZEPINEOXCARBAZEPINE
    51991-292OXCARBAZEPINEOXCARBAZEPINE
    55154-4959OxcarbazepineOxcarbazepine
    55700-569OxcarbazepineOxcarbazepine
    60429-063OXCARBAZEPINEOXCARBAZEPINE
    60429-062OXCARBAZEPINEOXCARBAZEPINE
    60429-061OXCARBAZEPINEOXCARBAZEPINE
    62756-184OxcarbazepineOxcarbazepine
    62756-183OxcarbazepineOxcarbazepine
    62756-185OxcarbazepineOxcarbazepine
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.